Mizuho on Evolus (EOLS): 'Medytox Selling Overhang Could End Soon', 'could enhance the stock's appeal to investors'
Tweet Send to a Friend
Mizuho analyst Vamil Divan reiterated an Outperform rating and $20.00 price target on Evolus (NASDAQ: EOLS).The analyst comments "The ownership ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
